EW Earnings Prediction
The chart below shows how EW performed 10 days before and after its earnings report, based on data from the past quarters. Typically, EW sees a +1.64% change in stock price 10 days leading up to the earnings, and a -7.86% change 10 days following the report. On the earnings day itself, the stock moves by -0.58%. This data can give you a slight idea of what to expect for the next quarter's release.
EW Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
1.35B
-8.54%
-2.27%
Gross Margin
80.59%
5.57%
1.49%
Operating Margin
29.11%
2.50%
6.94%
Net Margin
26.74%
3.20%
1.13%
EPS
5.13
714.29%
740.98%
No Data Available
EW Earnings Analysis
Edwards Lifesciences Corp Corporation (EW.N) Earnings Conference Call
Positive
Revenue Increase Overview: $1.4 billion in revenue, an increase of 10% on a constant currency basis versus the year-ago period, slightly ahead of expectations.
Catheter-Based Heart Therapy Growth: TAVR and TMTT both contributed significantly to growth in the third quarter as more patients globally benefited from our catheter-based structural heart therapies.
Clinical Research Advancements: Our team made important advancements in our clinical research and new product introduction to address the unmet needs of structural heart patients around the world.
Sales Growth Achievement: We achieved $91 million in sales for TMTT, representing 74% growth over the prior year, driven by strong global adoption of Edwards' premium surgical technologies.
Stock Repurchase Program: We repurchased $1 billion of stock through a combination of pre-established trading plans and accelerated share repurchase programs.
Negative
Earnings Decline in Q3: Earnings for Q3 2024 showed a decline in adjusted earnings per share to $0.67, slightly below expectations.
Sales Growth Decline: Sales from continuing operations were reported at $1.35 billion, reflecting a growth rate of only 9.6%, which is lower than previous quarters.
Rising Operating Expenses: Operating expenses increased to $421 million, representing 31.1% of sales, compared to $382 million in the prior year, indicating rising costs.
Sales Growth Outlook: The company anticipates lower sales growth in Q4 due to one-time items, which could impact overall performance for the year.
Sales Growth Guidance Stagnation: The guidance for full-year sales growth remains unchanged at 5% to 7%, suggesting a stagnation in growth expectations.
EW FAQs
How does EW typically perform around its earnings report dates?
Is Edwards Lifesciences Corporation (EW) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
EW Earning Call Sentiment
Edwards Lifesciences Corporation (EW) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
EW.N
0.3%Positive
The earnings call presents a mixed picture. Strong financial performance with a 9.6% sales increase and robust TMTT growth is offset by regulatory delays and regional pressures affecting TAVR sales. The Q&A reveals some uncertainties, particularly in Q4 guidance and management's vague responses on critical impacts. The share repurchase plan is a positive factor, but overall guidance adjustments and external challenges suggest a neutral market reaction.